Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer

28 Feb 2025

Abstract excerpt

Despite endocrine therapy (ET), approximately 20-40% of Stage I-III estrogen receptor-positive breast cancer (ER + BC) patients experience recurrence. Recurrence while on ET is indicative of ET resistance. This study aimed to identify differentially expressed genes (DEGs) associated with recurrence during ET (ET resistance) and to explore gene expression differences across PAM50 molecular subtypes. Eighty tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40021703
DOI: 10.1038/s41598-025-89274-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerPMID 40021703Read ↗

Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerSemantic proximity Read ↗

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read ↗

Secondary Analysis of Human Bulk RNA-seq Dataset Suggest Potential Mechanisms and Transcriptional Biomarkers for Letrozole Resistance in Estrogen Positive (ER+) Breast CancerSemantic proximity Read ↗

Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER + HER2 − Breast CancerSemantic proximity Read ↗

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohortSemantic proximity Read ↗

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read ↗

Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survivalSemantic proximity Read ↗

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read ↗

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrencesSemantic proximity Read ↗

A Novel Group of Genes that Causes Endocrine Resistance in Breast Cancer Identified by Dynamic Gene Expression AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.